Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from the Bartholin gland and is characterized by the presence of islands of uniform malignant cells forming cribriform patterns.
No clinical trials have been registered for Bartholin gland adenoid cystic carcinoma.
16 publications have been identified in PubMed for Bartholin gland adenoid cystic carcinoma. Research spans Case Report / Case Series (69%), Review / Meta-Analysis (19%), and Other (6%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 11 | 69% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 5:36 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Common questions about Bartholin gland adenoid cystic carcinoma
3 |
19% |
Other research | 1 | 6% |
Laboratory research | 1 | 6% |
Liss CM (2026). [PMID: 42180416](https://pubmed.ncbi.nlm.nih.gov/42180416/). *Gynecol Oncol Rep*. [Case Report / Case Series]
Bombon MF (2026). [PMID: 41873313](https://pubmed.ncbi.nlm.nih.gov/41873313/). *Cureus*. [Case Report / Case Series]
Ding Z (2026). [PMID: 41835178](https://pubmed.ncbi.nlm.nih.gov/41835178/). *Oncol Lett*. [Case Report / Case Series]
Palicelli A (2025). [PMID: 39996865](https://pubmed.ncbi.nlm.nih.gov/39996865/). *Curr Oncol*. [Review / Meta-Analysis]
Irfan H (2025). [PMID: 40756476](https://pubmed.ncbi.nlm.nih.gov/40756476/). *Radiol Case Rep*. [Case Report / Case Series]
Liu P (2025). [PMID: 40881491](https://pubmed.ncbi.nlm.nih.gov/40881491/). *World J Clin Cases*. [Case Report / Case Series]
Sato H (2025). [PMID: 41346905](https://pubmed.ncbi.nlm.nih.gov/41346905/). *Cureus*. [Case Report / Case Series]
Kostov S (2025). [PMID: 41375020](https://pubmed.ncbi.nlm.nih.gov/41375020/). *Cancers (Basel)*. [Review / Meta-Analysis]
Currie CC (2025). [PMID: 38661560](https://pubmed.ncbi.nlm.nih.gov/38661560/). *Int J Gynecol Pathol*. [Case Report / Case Series]
Liu C (2024). [PMID: 38736718](https://pubmed.ncbi.nlm.nih.gov/38736718/). *Gynecol Oncol Rep*. [Case Report / Case Series]
AI-curated news mentioning Bartholin gland adenoid cystic carcinoma
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.